DATA SHEET - Medsafe

ADVANTAN Presentation Uses - Medsafe

ADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.

  Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate

LOXALATE 1. Product Name - Medsafe Home Page

Page 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.

  Risks, Combination

DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …

New Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …

  Sheet, Data, Data sheet, Clexane

SEPTANEST Articaine hydrochloride 4% with …

SEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.

  Articaine

BOOSTRIX - Medsafe Home Page

1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.

  Information, Boostrix

NEW ZEALAND DATA SHEET - Medsafe

NEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a

  Cymevene

Edition Draft - Medsafe

Part 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for

  Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice

Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …

New Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …

  Product, Name, Sheet, Data, Data sheet 1 product name

NEW ZEALAND DATA SHEET MESTINON® - Medsafe

NEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to

  Myasthenia, Gravis, Myasthenia gravis, Mestinon

DATA SHEET PREDNISONE - Medsafe

• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since

  Myasthenia, Gravis, Myasthenia gravis, Prednisone

PHYSICIAN LABELING I. CIRCULATORY DISEASE MORTALITY …

PHYSICIAN LABELING 6065802 LEVLEN® 21 Tablets (levonorgestrel and ethinyl estradiol tablets) Patients should be counseled that this product does not protect against

  Disease, Physician, Mortality, Labeling, Circulatory, Levlen, Physician labeling i, Circulatory disease mortality

Which Oral Contraceptive Pill is Best for Me? - fainamd.com

1 Faina Novosolov, M.D. Which Oral Contraceptive Pill is Best for Me? Frederick R. Jelovsek MD, MS "I am 25 years old. I haven't had a period in about 6 months but I don't want to get pregnant now.

  Best, Which, Oral, Pill, Contraceptive, Which oral contraceptive pill is best

Women, Hormones, Mood and Sex-05.31

Outline •The Female Brain •Puberty, the Menstrual Cycle and PMDD •Pregnancy, Mood and Postpartum •Perimenopause, Mood and Sex •Menopause, Mood and Sex

Levlen ED CMI - Medsafe

1807 NZ LEVLEN ED CMI 3 • face) heart valve disorders or certain heart rhythm disorders • •migraine • cancer • hyperhomocysteinaemia, a

  Levlen

% of Women Continuing Use at One Year Method (1) Typical ...

1 % of Women Experiencing an Accidental Pregnancy within the First Year of Use % of Women Continuing Use at One Year3 Method (1) Typical Use1 (2) Perfect Use2 (3) (4) Chance4 85 85 Spermicides5 26 6 40 Periodic Abstinence

  Women, Continuing, Of women continuing use at one